Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
07
11
2018
accepted:
29
01
2019
entrez:
23
2
2019
pubmed:
23
2
2019
medline:
13
11
2019
Statut:
epublish
Résumé
IgA nephropathy (IgAN), the most common primary glomerulonephritis worldwide, has serious outcomes with end-stage renal disease developing in 30-50% of patients. The diagnosis requires renal biopsy. Due to its inherent risks, non-invasive approaches are needed. We evaluated 91 Czech patients with biopsy-proven IgAN who were assessed at time of diagnosis for estimated glomerular filtration rate (eGFR), proteinuria, microscopic hematuria, and hypertension, and then followed prospectively. Serum samples collected at diagnosis were analyzed for galactose-deficient IgA1 (Gd-IgA1) using new native-IgA1 and established neuraminidase-treated-IgA1 tests, Gd-IgA1-specific IgG autoantibodies, discriminant analysis and logistic regression model assessed correlations with renal function and Oxford classification (MEST score). Serum levels of native (P <0.005) and neuraminidase-treated (P <0.005) Gd-IgA1 were associated with the rate of eGFR decline. A higher relative degree of galactose deficiency in native serum IgA1 predicted a faster eGFR decline and poor renal survival (P <0.005). However, Gd-IgA1 has not differentiated patients with low vs. high baseline eGFR. Furthermore, patients with high baseline eGFR that was maintained during follow-up were characterized by low serum levels of Gd-IgA1-specific IgG autoantibodies (P = 0.003). Including levels of native and neuraminidase-treated Gd-IgA1 and Gd-IgA1-specific autoantibodies at diagnosis may aid in the prognostication of disease progression in Czech patients with IgAN. Future tests will assess utility of these biomarkers in larger patients cohorts from geographically distinct areas.
Sections du résumé
BACKGROUND
IgA nephropathy (IgAN), the most common primary glomerulonephritis worldwide, has serious outcomes with end-stage renal disease developing in 30-50% of patients. The diagnosis requires renal biopsy. Due to its inherent risks, non-invasive approaches are needed.
METHODS
We evaluated 91 Czech patients with biopsy-proven IgAN who were assessed at time of diagnosis for estimated glomerular filtration rate (eGFR), proteinuria, microscopic hematuria, and hypertension, and then followed prospectively. Serum samples collected at diagnosis were analyzed for galactose-deficient IgA1 (Gd-IgA1) using new native-IgA1 and established neuraminidase-treated-IgA1 tests, Gd-IgA1-specific IgG autoantibodies, discriminant analysis and logistic regression model assessed correlations with renal function and Oxford classification (MEST score).
RESULTS
Serum levels of native (P <0.005) and neuraminidase-treated (P <0.005) Gd-IgA1 were associated with the rate of eGFR decline. A higher relative degree of galactose deficiency in native serum IgA1 predicted a faster eGFR decline and poor renal survival (P <0.005). However, Gd-IgA1 has not differentiated patients with low vs. high baseline eGFR. Furthermore, patients with high baseline eGFR that was maintained during follow-up were characterized by low serum levels of Gd-IgA1-specific IgG autoantibodies (P = 0.003).
CONCLUSIONS
Including levels of native and neuraminidase-treated Gd-IgA1 and Gd-IgA1-specific autoantibodies at diagnosis may aid in the prognostication of disease progression in Czech patients with IgAN. Future tests will assess utility of these biomarkers in larger patients cohorts from geographically distinct areas.
Identifiants
pubmed: 30794576
doi: 10.1371/journal.pone.0212254
pii: PONE-D-18-32069
pmc: PMC6386256
doi:
Substances chimiques
Autoantibodies
0
Biomarkers
0
Immunoglobulin A
0
Galactose
X2RN3Q8DNE
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0212254Subventions
Organisme : NIDDK NIH HHS
ID : K01 DK106341
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK078244
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK082753
Pays : United States
Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest concerning their work in this study. In the interest of full disclosure, we report that JN is a co-founder of Reliant Glycosciences, LLC. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Nat Genet. 2014 Nov;46(11):1187-96
pubmed: 25305756
J Am Soc Nephrol. 2007 Dec;18(12):3177-83
pubmed: 17978307
Kidney Int. 2010 Mar;77(5):417-27
pubmed: 20016469
J Am Soc Nephrol. 2017 Feb;28(2):691-701
pubmed: 27612994
Kidney Int. 2007 Jun;71(11):1148-54
pubmed: 17342176
Expert Opin Med Diagn. 2013 Nov;7(6):615-27
pubmed: 24175678
N Engl J Med. 2013 Jun 20;368(25):2402-14
pubmed: 23782179
Adv Chronic Kidney Dis. 2014 Mar;21(2):205-16
pubmed: 24602470
PLoS Genet. 2017 Feb 10;13(2):e1006609
pubmed: 28187132
PLoS One. 2014 Jun 11;9(2):e99026
pubmed: 24918438
J Am Soc Nephrol. 2011 Oct;22(10):1795-803
pubmed: 21949093
J Clin Invest. 2009 Jun;119(6):1668-77
pubmed: 19478457
J Biol Chem. 2014 Feb 21;289(8):5330-9
pubmed: 24398680
Nephrol Dial Transplant. 2008 Jun;23(6):1931-9
pubmed: 18178603
PLoS Genet. 2012;8(6):e1002765
pubmed: 22737082
J Am Soc Nephrol. 2017 Jul;28(7):2158-2166
pubmed: 28209808
J Am Soc Nephrol. 2012 Sep;23(9):1579-87
pubmed: 22904352
Kidney Int. 2009 Sep;76(5):534-45
pubmed: 19571791
Kidney Int. 2016 Jan;89(1):167-75
pubmed: 26759049
Clin J Am Soc Nephrol. 2011 Aug;6(8):1903-11
pubmed: 21784819
Kidney Int. 2012 Oct;82(7):790-6
pubmed: 22673888